Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients

NCT00424606 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

658

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Docetaxel
DRUG: Epirubicin
DRUG: Epirubicin
DRUG: Docetaxel

Sponsor

Hellenic Oncology Research Group

Collaborators

[object Object]